The results highlight the need for close monitoring and optimized multidisciplinary care for long-term adverse events after COVID-19 in patients with rheumatic disease.
Despite the recent advancements in the treatment of polymyalgia rheumatica, a need for more research focused on finding non-steroidal treatment options remains.